Releases
  • All
More
About Gaush Meditech
Gaush Meditech Ltd is a China-based company mainly engaged in ophthalmology medical business. The Company operates in four segments. Proprietary Products segment develops and produces surgical equipment and related supporting software, intra optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables. Distribution segment sells brand ophthalmic medical devices and consumables. Technical Services segment provides warranty service, maintenance service and consumables related to after-sales service. Others segment is mainly engaged in equipment leasing business and intellectual property agency services. The Company's products are widely used in the examination, treatment and correction of ophthalmic subspecialty diseases such as fundus disease, cataract, glaucoma, refraction, optometry, ocular surface, and children's ophthalmology.
More
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.